A case series analysis of encephalitis events reported to the Sponsor for patients treated with nivolumab to assess the risk factors and outcomes of immune-mediated encephalitis.

Inclusion Criteria:

• Moderate, severe, life-threatening or fatal encephalitis events occurring in patients treated with nivolumab and reported to the Sponsor

Exclusion Criteria:

• Encephalitis cases identified through literature reviews and not reported to the Sponsor
• Encephalitis cases identified from company-sponsored observational studies with secondary data collection
• Spontaneous reports not submitted directly to the Sponsor

Other protocol-defined inclusion/exclusion criteria apply

Case series reported to the sponsor from various health care facilities